-transparent.png){kind=logo}
Cyclin-dependent kinases (Cdks) previously have been shown to drive the major cell cycle transitions in eukaryotic organisms ranging from yeast to humans. We report here the identification of a 28-kDa protein, p28Ick (inhibitor of cyclin-dependent kinase), that binds to and inhibits the kinase activity of preformed Cdk/cyclin complexes from human cells. p28 inhibitory activity fluctuates during the cell cycle with maximal levels in G1 and accumulates in G1- and G0-arrested cells. These results suggest that control of the G1/S transition may be influenced by a family of Cdk inhibitors that include p28Ick and the recently described inhibitors p21Cip1/Waf1/Cap20 and p16Ink4.
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
March 1996,
Molecular biology of the cell,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
November 1991,
Trends in cell biology,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
September 1996,
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
February 2018,
The Plant cell,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
July 2002,
Chembiochem : a European journal of chemical biology,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
January 2002,
Bioscience reports,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
February 1995,
The Journal of biological chemistry,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
December 1994,
Chemistry & biology,
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
December 1993,
Science (New York, N.Y.),
L Hengst, and
V Dulic, and
J M Slingerland, and
E Lees, and
S I Reed
July 1997,
Anti-cancer drugs,
